Antiplatelet Medications Are Associated With Bleeding and Decompensation Events Among Patients With Cirrhosis.

ABSTRACT:

Background

In an aging population with cardiovascular comorbidities, anticoagulant (AC), antiplatelet (AP), and nonsteroidal anti-inflammatory drug (NSAID) use are increasing. It remains unclear whether these agents pose increased bleeding risk in cirrhosis. This study aimed to assess the association between these medications and bleeding and portal hypertension complications in cirrhosis.

Methods

The IMS PharMetrics database was used to identify privately insured adults diagnosed with cirrhosis from 2007 to 2015, stratified as compensated or decompensated based on the presence of portal hypertensive complications 1 year before cirrhosis diagnosis. Bleeding or decompensation outcomes were assessed 6 to 18 months after cirrhosis diagnosis using a landmark analysis design. Mul

SUBMITTER: Lieber SR 

PROVIDER: S-EPMC8627524 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature